In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

Source: 
Endpoints
snippet: 

BeiGene may have made its rep as a PD-1 pioneer in China, but it’s coming to the US with more cancer drugs in its arsenal.